Barrett Elizabeth's most recent trade in Sage Therapeutics Inc was a trade of 21,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sage Therapeutics Inc | Elizabeth Barrett | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Jul 2025 | 21,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Elizabeth Barrett | Director | 31 Jul 2025 | 3,000 | 0 (0%) | 0% | - | Common Stock | ||
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2025 | 87,615 | 87,615 | - | - | Performance Stock Units | |
| Allogene Therapeutics Inc | Elizabeth Barrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 95,400 | 95,400 | - | - | Restricted Stock Unit | |
| Sage Therapeutics Inc | Elizabeth Barrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 21,500 | 21,500 | - | - | Stock Option (Right to Buy) | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 96,377 | 96,377 | - | - | Restricted Stock Units | |
| Sage Therapeutics Inc | Elizabeth Barrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Elizabeth Barrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 191,082 | 191,082 | - | - | Stock Option (Right to buy) | |
| UroGen Pharma Ltd | Barrett Elizabeth | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 87,615 | 87,615 | - | - | Restricted Stock Units | |
| Sage Therapeutics Inc | Elizabeth Barrett | Director | Purchase of securities on an exchange or from another person at price $ 18.64 per share. | 09 Aug 2023 | 2,000 | 3,000 (0%) | 0% | 18.6 | 37,279 | Common Stock |
| Sage Therapeutics Inc | Elizabeth Barrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Elizabeth Barrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 116,120 | 116,120 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Elizabeth Barrett | Director | Purchase of securities on an exchange or from another person at price $ 50.50 per share. | 09 May 2023 | 1,000 | 1,000 (0%) | 0% | 50.5 | 50,500 | Common Stock |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 100,000 | 100,000 | - | - | Performance Stock Units | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 75,000 | 75,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 13,333 | 13,334 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 13,333 | 326,691 (1%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 5,000 | 0 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 5,000 | 313,358 (1%) | 0% | - | Ordinary Shares | |
| Sage Therapeutics Inc | Elizabeth Barrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,947 | 9,947 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Elizabeth Barrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 71,070 | 71,070 | - | - | Stock Option (Right to Buy) | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 13,333 | 26,667 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 13,333 | 314,318 (1%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.58 per share. | 31 Jan 2022 | 5,960 | 308,358 (1%) | 0% | 7.6 | 45,177 | Ordinary Shares |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 5,000 | 303,220 (1%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 5,000 | 5,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.58 per share. | 31 Jan 2022 | 2,235 | 300,985 (1%) | 0% | 7.6 | 16,941 | Ordinary Shares |
| Sage Therapeutics Inc | Elizabeth Barrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2022 | 2,048 | 2,048 | - | - | Stock Options (Right to buy) | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 105,689 | 0 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 105,689 | 345,188 (1%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 9.15 per share. | 03 Jan 2022 | 46,968 | 298,220 (1%) | 0% | 9.1 | 429,757 | Ordinary Shares |
| Allogene Therapeutics Inc | Elizabeth Barrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2021 | 63,385 | 63,385 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Elizabeth Barrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Sage Therapeutics Inc | Elizabeth Barrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2021 | 915 | 915 | - | - | Stock Options (Right to buy) | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2021 | 8,807 | 105,689 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2021 | 8,807 | 237,924 (1%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2021 | 5,000 | 10,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2021 | 5,000 | 242,924 (1%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.51 per share. | 03 Jan 2021 | 2,185 | 240,739 (1%) | 0% | 17.5 | 38,257 | Ordinary Shares |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.51 per share. | 03 Jan 2021 | 1,240 | 239,499 (1%) | 0% | 17.5 | 21,711 | Ordinary Shares |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 18.50 per share. | 14 Dec 2020 | 10,000 | 229,117 (1%) | 0% | 18.5 | 185,000 | Ordinary Shares |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 61,652 | 219,117 (1%) | 0% | 0 | Ordinary Shares | |
| UroGen Pharma Ltd | Elizabeth Barrett | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 61,652 | 114,496 | - | - | Restricted Stock Units |